Patents by Inventor Xuhang Li

Xuhang Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10849915
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: December 1, 2020
    Assignee: The Johns Hopkins University
    Inventors: Barbara Slusher, Rana Rais, Xuhang Li
  • Patent number: 10730916
    Abstract: The present invention features biomarkers capable of diagnosing inflammatory bowel disease and methods of using such biomarkers to diagnose and selecting treatments for inflammatory bowel diseases.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 4, 2020
    Assignee: The Johns Hopkins University
    Inventors: Xuhang Li, Heng Zhu
  • Patent number: 10709740
    Abstract: Disclosed is a composition including: an isolated in vitro pre-conditioned population of adult bone marrow derived mesenchymal stem cells (BMSCs), wherein the BMSCs express neuronal markers, and wherein the neuronal markers are PGP9.5, NSE, Tuj1, HuC/D and neuronal nitric oxide synthase (nNOS). Methods of preparing the BMSCs are also provided. In addition, the present disclosure is directed to a method of treating an enteric nervous system-related disorder including: administering to a subject in need thereof a pharmaceutical composition including the in vitro pre-conditioned BMSC population and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: July 14, 2020
    Assignees: THE JOHNS HOPKINS UNIVERSITY, UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Xuhang Li, Xiaohua Hou, Rong Lin
  • Publication number: 20200038381
    Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
    Type: Application
    Filed: August 14, 2019
    Publication date: February 6, 2020
    Inventors: Zhaoli Sun, Xuhang Li
  • Publication number: 20190358267
    Abstract: Disclosed is a composition including: an isolated in vitro pre-conditioned population of adult bone marrow derived mesenchymal stem cells (BMSCs), wherein the BMSCs express neuronal markers, and wherein the neuronal markers are PGP9.5, NSE, Tuj1, HuC/D and neuronal nitric oxide synthase (nNOS). Methods of preparing the BMSCs are also provided. In addition, the present disclosure is directed to a method of treating an enteric nervous system-related disorder including: administering to a subject in need thereof a pharmaceutical composition including the in vitro pre-conditioned BMSC population and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2019
    Publication date: November 28, 2019
    Inventors: Xuhang LI, Xiaohua HOU, Rong LIN
  • Patent number: 10478458
    Abstract: Disclosed is a composition including: an isolated in vitro pre-conditioned population of adult bone marrow derived mesenchymal stem cells (BMSCs), wherein the BMSCs express neuronal markers, and wherein the neuronal markers are PGP9.5, NSE, Tuj1, HuC/D and neuronal nitric oxide synthase (nNOS). Methods of preparing the BMSCs are also provided. In addition, the present disclosure is directed to a method of treating an enteric nervous system-related disorder including: administering to a subject in need thereof a pharmaceutical composition including the in vitro pre-conditioned BMSC population and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: November 19, 2019
    Assignees: THE JOHNS HOPKINS UNIVERSITY, UNION HOSPITAL, TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Xuhang Li, Xiaohua Hou, Rong Lin
  • Publication number: 20190314344
    Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
    Type: Application
    Filed: July 31, 2015
    Publication date: October 17, 2019
    Inventors: Zhaoli Sun, Xuhang Li
  • Patent number: 10420751
    Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 24, 2019
    Assignee: MedRegen, LLC
    Inventors: Zhaoli Sun, Xuhang Li
  • Publication number: 20190076447
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Application
    Filed: November 14, 2018
    Publication date: March 14, 2019
    Inventors: Barbara Slusher, Rana Rais, Xuhang Li
  • Patent number: 10172873
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: January 8, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara Slusher, Rana Rais, XUHANG Li
  • Publication number: 20170224709
    Abstract: Methods and compounds are disclosed for treating inflammatory bowel disease (IBD) by using Prostate Specific Membrane Antigen (PSMA) inhibitors.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 10, 2017
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: BARBARA SLUSHER, RANA RAIS, XUHANG LI
  • Publication number: 20170095511
    Abstract: Disclosed is a composition including: an isolated in vitro pre-conditioned population of adult bone marrow derived mesenchymal stem cells (BMSCs), wherein the BMSCs express neuronal markers, and wherein the neuronal markers are PGP9.5, NSE, Tuj1, HuC/D and neuronal nitric oxide synthase (nNOS). Methods of preparing the BMSCs are also provided. In addition, the present disclosure is directed to a method of treating an enteric nervous system-related disorder including: administering to a subject in need thereof a pharmaceutical composition including the in vitro pre-conditioned BMSC population and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 3, 2016
    Publication date: April 6, 2017
    Inventors: Xuhang LI, Xiaohua HOU, Rong LIN
  • Publication number: 20170059581
    Abstract: The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease. In one embodiment, a method for diagnosing Crohn's Disease (CD) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the levels of at least one cytokine in the sample collected from the patient; and (c) comparing the levels of the at least one cytokine with predefined cytokine levels, wherein a correlation between the cytokine levels in the patient sample and predefined cytokine levels indicates that the patient has CD. In a specific embodiment, the at least one cytokine comprises Interferon (IFN)-gamma, Interleukin (IL)-1beta, IL-6, IL-8, IL-12, IL-17 and CXCL10.
    Type: Application
    Filed: September 7, 2016
    Publication date: March 2, 2017
    Inventors: Xuhang Li, Philip J. Alex, Michael B. Centola, Nicholas Knowlton
  • Publication number: 20160370381
    Abstract: The present invention features biomarkers capable of diagnosing inflammatory bowel disease and methods of using such biomarkers to diagnose and selecting treatments for inflammatory bowel diseases.
    Type: Application
    Filed: May 20, 2016
    Publication date: December 22, 2016
    Inventors: Xuhang Li, Heng Zhu
  • Patent number: 9434771
    Abstract: The present invention features biomarkers capable of diagnosing inflammatory bowel disease and methods of using such biomarkers to diagnose and selecting treatments for inflammatory bowel diseases.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: September 6, 2016
    Assignee: The Johns Hopkins University
    Inventors: Xuhang Li, Heng Zhu
  • Publication number: 20160008331
    Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
    Type: Application
    Filed: July 31, 2015
    Publication date: January 14, 2016
    Inventors: Zhaoli Sun, Xuhang Li
  • Publication number: 20140128276
    Abstract: Methods, devices, and kits for diagnosing or evaluating irritable bowel syndrome employ an analysis for the presence and amount of specific cytokines. The levels of such cytokines provide an index for diagnosis and/or evaluation of therapeutic response. Samples to be tested include peripheral blood, serum, plasma, or tissue from a human subject having or suspected of having Irritable Bowel Syndrome.
    Type: Application
    Filed: January 13, 2012
    Publication date: May 8, 2014
    Applicants: OKLAHOMA MEDICAL RESEARCH FOUNDATION, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Xuhang Li, Philip Alex, Michael Centola, Nicholas Knowlton
  • Publication number: 20130303391
    Abstract: The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease. In one embodiment, a method for diagnosing Crohn's Disease (CD) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the levels of at least one cytokine in the sample collected from the patient; and (c) comparing the levels of the at least one cytokine with predefined cytokine levels, wherein a correlation between the cytokine levels in the patient sample and predefined cytokine levels indicates that the patient has CD. In a specific embodiment, the at least one cytokine comprises Interferon (IFN)-gamma, Interleukin (IL)-1beta, IL-6, IL-8, IL-12, IL-17 and CXCL10.
    Type: Application
    Filed: September 14, 2011
    Publication date: November 14, 2013
    Applicants: OKLAHOMA MEDICAL RESEARCH FOUNDATION, The Johns Hopkins University
    Inventors: Xuhang Li, Philip J. Alex, Michael B. Centola, Nicholas Knowlton
  • Publication number: 20130197028
    Abstract: Agonists and antagonists of nAChR?7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed. Agonists and antagonists of nAChR?7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed.
    Type: Application
    Filed: June 24, 2011
    Publication date: August 1, 2013
    Applicants: OKLAHOMA MEDICAL RESEARCH FOUNDATION, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Xuhang Li, Philip Alex, Michael B. Centola
  • Publication number: 20110251100
    Abstract: The present invention features biomarkers capable of diagnosing inflammatory bowel disease and methods of using such biomarkers to diagnose and selecting treatments for inflammatory bowel diseases.
    Type: Application
    Filed: December 17, 2009
    Publication date: October 13, 2011
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Xuhang Li, Heng Zhu